Clinical trials: Prostatic Disease
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance.
- Trial name
- NCT00630344
- Testing
- RAD001, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Obtain PSMA-PET imaging preoperatively and calculate performance for predicting extra-prostatic extension based on whole-mount pathology (gold standard).
- Trial name
- NCT04936334
- Testing
- 68Ga-PSMA-11 PET Scan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Clinton Bahler
Prostate Cancer, Hot Flashes
(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
Androgen Deprivation Therapy (ADT) is a critical component of advanced prostate cancer treatment but causes numerous adverse effects including decreased bone mass, decreased muscle mass, gynecomastia, erectile dysfunction, loss…
- Trial name
- NCT03796195
- Testing
- .5% Bupivacaine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Prostatic Neoplasms, Pelvic Nodal
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
This phase II trial studies the safety of giving enzalutamide with leuprolide acetate before and after radiation therapy and to see how well it works in treating patients with prostate cancer that is at high risk of returning.
- Trial name
- NCT02508636
- Testing
- Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Primary Objectives: To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in…
- Trial name
- NCT01511536
- Testing
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Sanofi
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
- Trial name
- NCT03803475
- Testing
- Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
- Where
- United States
- Volunteers
- 485 people
- Sponsor
- Thomas Hope
Prostate Cancer, Prostatectomy
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
The purpose of this study is to look at blood and tissue samples for changes following the use of Sunitinib malate. Additionally, we would like to find out if the drug, Sunitinib malate, is safe and works in men with prostate…
- Trial name
- NCT00672594
- Testing
- Sunitinib Malate
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Prostate Cancer
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
The purpose of this study is to describe the 2 year progression-free survival in men with recurrent PSA-only disease after prostatectomy receiving combined enzalutamide and standard androgen-deprivation therapy (ADT) with salvage…
- Trial name
- STREAM (NCT02057939)
- Testing
- enzalutamide, Androgen Deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Prostatitis
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prostatitis/chronic pelvic pain syndrome…
- Trial name
- NCT00103402
- Testing
- Alfuzosin
- Where
- 10 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prostate Cancer
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.
- Trial name
- NCT00587431
- Testing
- GnRh (Leuprolide), Testosterone Gel, Docetaxel
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
The primary objectives of the study are: To evaluate feasibility, safety and tolerance of 6 months administration of Revlimid at 5mg/day and 25mg/day, given orally in subjects with prostate cancer with evidence of biochemical…
- Trial name
- NCT00348595
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Male Hypogonadism, Muscle Atrophy
5-Alpha Reductase and Anabolic Effects of Testosterone
The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.
- Conditions
- Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
- Trial name
- NCT00475501
- Testing
- Testosterone Enanthate, Finasteride
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the…
- Trial name
- NCT00783094
- Testing
- Tadalafil 2.5 mg, Tadalafil 5 mg
- Where
- 6 sites in Japan
- Volunteers
- 422 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for…
- Trial name
- UPWARD (NCT01977651)
- Testing
- Enzalutamide
- Where
- 76 sites in United States, Argentina and 18 more
- Volunteers
- 424 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.
- Trial name
- NCT00195039
- Testing
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Efficacy of a Couple-Focused mHealth Symptom Self-management Program
In this study, the investigators propose to test the efficacy of a couple-focused, web-based tailored prostate cancer symptom management program, Prostate Cancer Education and Resources for Couples (PERC) in a randomized clinical…
- Trial name
- NCT03489057
- Testing
- Prostate Cancer Education and Resources for Couples (PERC), usual care plus NCI website
- Where
- United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.